Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 34

Sort by

Sort Order Select

Journal Articles

Iptacopan Monotherapy in Patients with Cold Agglutinin Disease: Phase II Study Results

Alexander Röth, Wilma Barcellini, Christine Ademokun, Shripad Chitnis, Sofiya Matviykiv, Alessandra Vitaliti, Chi Chen, Vasiliki Katsanou, Raghav Chawla, Hanny Al-Samkari

Blood (2024) 144 (Supplement 1): 2457.

https://doi.org/10.1182/blood-2024-199637

Published: 2024

Journal Articles

VISTA Is the Predominant 2nd Generation of ICI (Immune Check-Point Inhibitor) in Ph(-) myeloproliferative Neoplasm

Jen-Chin Wang, Chi Chen, Kapilkumar Manvar, Boris Avezbakiyev, Hesham Ali Abowali, Omid Heravi

Blood (2023) 142 (Supplement 1): 6351.

https://doi.org/10.1182/blood-2023-178576

Published: 2023

Journal Articles

Blockade of Common Gamma Chain Cytokine Signaling with REGN7257, an Interleukin 2 Receptor Gamma (IL2RG) Monoclonal Antibody, in Combination with Costimulatory Blockers Delayed Skin Graft Rejection in Mice

Audrey Le Floch-Ramondou, George Scott, Wen-Chi Chen, Kirsten Nagashima, Andrew Murphy, Matthew Sleeman, Jamie Orengo

Blood (2023) 142 (Supplement 1): 2550.

https://doi.org/10.1182/blood-2023-189129

Published: 2023

Journal Articles

The non-cell-autonomous function of ID1 promotes AML progression via ANGPTL7 from the microenvironment

Blood (2023) 142 (10): 903–917.

https://doi.org/10.1182/blood.2022019537

Published: 2023

Includes: Supplemental data

Journal Articles

In Vitro Drug Studies of Inhibiting MDSC to Improve Efficacy of ICI (immune check point inhibitor) Therapy in Ph(-) myeloproliferative Neoplasm

Jen-Chin Wang, Calvin Chi Chen, Kapilkumar Manvar, Lishi Sun, Gardith Joseph, Ching Wong

Blood (2022) 140 (Supplement 1): 12187–12188.

https://doi.org/10.1182/blood-2022-158403

Published: 2022

Journal Articles

Elevated Levels of PD-L1 on MDSCs in Patients with Ph(-) Myeloproliferative Neoplasm

Jen-Chin Wang, Chi Chen, Vladimir Gotlieb, Sos Nalghranyan, Ching Wong, Isabel Yeo

Blood (2021) 138 (Supplement 1): 4591.

https://doi.org/10.1182/blood-2021-148260

Published: 2021

Journal Articles

Phase 2 Results of Urinary-Derived Human Chorionic Gonadotropin/Epidermal Growth Factor As Treatment for Life-Threatening Acute Gvhd

Blood (2021) 138 (Supplement 1): 261.

https://doi.org/10.1182/blood-2021-145008

Published: 2021

Journal Articles

TLR, RAGE, and HMGB1 in the Inflammatory Response in Ph(-) Myeloproliferative Neoplasm

Guanfang Shi, PhD, Kiron Nair, MD, Preethi Ramachandran, MD, Chi Chen, MD PhD, Ching Wong, MD, Gardith Joseph, MD, Vladimir Gotlieb, MD, Maksim Liaukovich, MD, Jen-Chin Wang, MD

Blood (2020) 136 (Supplement 1): 31–32.

https://doi.org/10.1182/blood-2020-134988

Published: 2020

Journal Articles

Plasma Short Chain Fatty Acids As a Predictor of Response to Therapy for Life-Threatening Acute Graft-Versus-Host Disease

Parth Gandhi, Isha Gandhi, Andrea Hoeschen, Wes Mosher, Margaret L. MacMillan, MD, Armin Rashidi, MD PhD, Najla H El Jurdi, MD, Alexander Khoruts, MD, Daniel J. Weisdorf, MD, Bruce R. Blazar, MD, Qing Cao, MS, Brian C. Betts, MD, Angela Panoskaltsis-Mortari, PhD, Chi Chen, Shernan G Holtan, MD

Blood (2020) 136 (Supplement 1): 14.

https://doi.org/10.1182/blood-2020-140117

Published: 2020

Journal Articles

JAK2 V617F Mutation Negative Polycythemia Diagnosed By IGF-1R, EEC Formation , and IRS2 over Expressions

Guanfang Shi, PhD, Chi Chen, MD PhD, Maksim Liaukovich, MD, Vladimir Gotlieb, MD, Jen-Chin Wang, MD

Blood (2020) 136 (Supplement 1): 14–15.

https://doi.org/10.1182/blood-2020-134863

Published: 2020

Journal Articles

Programmed Cell Death Receptor (PD-1), PD-1 Ligand (PD-L1) Expression in Philadelphia Chromosome Negative Myeloid Neoplasms

Chi Chen, MD PhD, Anita Pandey, MBBS, MD, Ajay Kundra, MD, Sreenath Kodali, MBBS, MD, Ching Wong, MD, Tony W. Cheung, MD, Vladimir K. Gotlieb, MD, Gardith Joseph, MD, Sophia Tribie, Jen-Chin Wang, MD

Blood (2018) 132 (Supplement 1): 4302.

https://doi.org/10.1182/blood-2018-99-112393

Published: 2018

Journal Articles

Preliminary Results from a Phase Ib Study Evaluating BCL-2 Inhibitor Venetoclax in Combination with MEK Inhibitor Cobimetinib or MDM2 Inhibitor Idasanutlin in Patients with Relapsed or Refractory (R/R) AML

Naval Daver, MD, Daniel A. Pollyea, MD, Karen W.L. Yee, MD, Pierre Fenaux, MD PhD, Joseph M. Brandwein, MD FRCPC, Norbert Vey, Giovanni Martinelli, Kevin R Kelly, MD PhD, Gail J. Roboz, MD, Jacqueline S. Garcia, Arnaud Pigneux, MD PhD, Smita Kshirsagar, Monique Dail, Jue Wang, Mehrdad Mobasher, Lin-Chi Chen, Wan-Jen Hong, Marina Konopleva, MD PhD, Michael Andreeff, MD PhD

Blood (2017) 130 (Supplement 1): 813.

https://doi.org/10.1182/blood.V130.Suppl_1.813.813

Published: 2017

Journal Articles

Monocytic Myeloid-Derived Suppressor Cells (Mo-MDSC) Are Increased but Not M1 or M2 TAM Macrophages in the Bone Marrow of Patients with BCR-ABL Negative Myeloid Neoplasm (MPN)

Chi Chen, MD PhD, Andrei Bandarchuk, MD, Ching Wong, MD, Vladimir K. Gotlieb, MD, Hamza Minhas, MBBS, Gardith Joseph, MD, Sophia Tribie, Jen-Chin Wang, MD

Blood (2017) 130 (Supplement 1): 5266.

https://doi.org/10.1182/blood.V130.Suppl_1.5266.5266

Published: 2017

Journal Articles

Minimal Residual Disease (MRD) Assessment By Multiparametric Flow Cytometry Is Prognostic for Progression-Free Survival in Phase 1/1b Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients Treated with Idasanutlin MDM2 Antagonist

Benjamin Lanza, Giovanni Martinelli, Karen W.L. Yee, MD, Lori Jukofsky, Bernhard Reis, PhD, Steven Blotner, PhD, Mark W. Drummond, PhDMD, Norbert Vey, MD PhD, Karen Seiter, MD, Michael J. Dickinson, MBBS, FRACP, FRCPA, Kevin R. Kelly, MD PhD, Margaret Kasner, MD, Michel Theron, PhD, Jeffrey M. Venstrom, Steven Middleton, PhD, Lin-Chi Chen, MD PhD, Nelson Kinnersley, Gwen Nichols, MD, William E. Pierceall, PhD

Blood (2016) 128 (22): 2843.

https://doi.org/10.1182/blood.V128.22.2843.2843

Published: 2016

Journal Articles

Clinical Response to Idasanutlin (RG7388) in Acute Myeloid Leukemia Patients Is Associated with Pre-Treatment MDM2 Protein Expression in Leukemic Blasts and Leukemic Stem Cells

Blood (2015) 126 (23): 2580.

https://doi.org/10.1182/blood.V126.23.2580.2580

Published: 2015

Journal Articles

Comparison of Ruxolitinib , Momelotinib, and Pacritinib in the Inhibition of Immune Differentiation and Proliferation of T Cells in Myeloproliferative Neoplasm

Chi Chen, MD PhD, Hemant Sindhu, MD, Ajay Kundra, MD, Maryna Yarotska, MD, Tony W. Cheung, MD, Jen-Chin Wang, MD

Blood (2015) 126 (23): 5203.

https://doi.org/10.1182/blood.V126.23.5203.5203

Published: 2015

Journal Articles

Phase 1/1b Study of RG7388, a Potent MDM2 Antagonist, in Acute Myelogenous Leukemia (AML) Patients (Pts)

Blood (2014) 124 (21): 116.

https://doi.org/10.1182/blood.V124.21.116.116

Published: 2014

Journal Articles

Programmed Cell Death Receptor (PD-1), PD-1 Ligand (PD-L1) Expression and Myeloid Derived Suppressor Cells (MDSC) In Myeloid Neoplasms Implicate The Mechanism Of IMiD Treatment Of Myelofibrosis

Ajay Kundra, MD, Stacey Baptiste, MD, Chi Chen, MD, Ph, D, Hemant Sindhu, MD, Jen-Chin Wang, MD

Blood (2013) 122 (21): 2837.

https://doi.org/10.1182/blood.V122.21.2837.2837

Published: 2013

Journal Articles

Immune Derangements in Patients with Myelofibrosis- the Role of T reg, Th17, and sIL2α

Hemant Sindhu, MD, Ajay Kundra, Chi Chen, MD, Ph.D, Jen-Chin Wang, MD

Blood (2012) 120 (21): 1763.

https://doi.org/10.1182/blood.V120.21.1763.1763

Published: 2012

Journal Articles

Changes of Megakaryocyte Gene Expression When Essential Thrombocythemia (ET) Transform Into Myelofibrosis (Post-ET MF) by Microarray Analysis,

Hemant Sindhu, MD, Chi Chen, MD, Ph.D, Muhammad I. Kafeel, MD, Yiwu Sun, MD, Ph D, Ching Wong, MD, Jen-Chin Wang, MD

Blood (2011) 118 (21): 3845.

https://doi.org/10.1182/blood.V118.21.3845.3845

Published: 2011

NARROW

Iptacopan Monotherapy in Patients with Cold Agglutinin Disease: Phase II Study Results

VISTA Is the Predominant 2nd Generation of ICI (Immune Check-Point Inhibitor) in Ph(-) myeloproliferative Neoplasm

Blockade of Common Gamma Chain Cytokine Signaling with REGN7257, an Interleukin 2 Receptor Gamma (IL2RG) Monoclonal Antibody, in Combination with Costimulatory Blockers Delayed Skin Graft Rejection in Mice

The non-cell-autonomous function of ID1 promotes AML progression via ANGPTL7 from the microenvironment

In Vitro Drug Studies of Inhibiting MDSC to Improve Efficacy of ICI (immune check point inhibitor) Therapy in Ph(-) myeloproliferative Neoplasm

Elevated Levels of PD-L1 on MDSCs in Patients with Ph(-) Myeloproliferative Neoplasm

Phase 2 Results of Urinary-Derived Human Chorionic Gonadotropin/Epidermal Growth Factor As Treatment for Life-Threatening Acute Gvhd

TLR, RAGE, and HMGB1 in the Inflammatory Response in Ph(-) Myeloproliferative Neoplasm

Plasma Short Chain Fatty Acids As a Predictor of Response to Therapy for Life-Threatening Acute Graft-Versus-Host Disease

JAK2 V617F Mutation Negative Polycythemia Diagnosed By IGF-1R, EEC Formation , and IRS2 over Expressions

Programmed Cell Death Receptor (PD-1), PD-1 Ligand (PD-L1) Expression in Philadelphia Chromosome Negative Myeloid Neoplasms

Preliminary Results from a Phase Ib Study Evaluating BCL-2 Inhibitor Venetoclax in Combination with MEK Inhibitor Cobimetinib or MDM2 Inhibitor Idasanutlin in Patients with Relapsed or Refractory (R/R) AML

Monocytic Myeloid-Derived Suppressor Cells (Mo-MDSC) Are Increased but Not M1 or M2 TAM Macrophages in the Bone Marrow of Patients with BCR-ABL Negative Myeloid Neoplasm (MPN)

Minimal Residual Disease (MRD) Assessment By Multiparametric Flow Cytometry Is Prognostic for Progression-Free Survival in Phase 1/1b Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients Treated with Idasanutlin MDM2 Antagonist

Clinical Response to Idasanutlin (RG7388) in Acute Myeloid Leukemia Patients Is Associated with Pre-Treatment MDM2 Protein Expression in Leukemic Blasts and Leukemic Stem Cells

Comparison of Ruxolitinib , Momelotinib, and Pacritinib in the Inhibition of Immune Differentiation and Proliferation of T Cells in Myeloproliferative Neoplasm

Phase 1/1b Study of RG7388, a Potent MDM2 Antagonist, in Acute Myelogenous Leukemia (AML) Patients (Pts)

Programmed Cell Death Receptor (PD-1), PD-1 Ligand (PD-L1) Expression and Myeloid Derived Suppressor Cells (MDSC) In Myeloid Neoplasms Implicate The Mechanism Of IMiD Treatment Of Myelofibrosis

Immune Derangements in Patients with Myelofibrosis- the Role of T reg, Th17, and sIL2α

Changes of Megakaryocyte Gene Expression When Essential Thrombocythemia (ET) Transform Into Myelofibrosis (Post-ET MF) by Microarray Analysis,

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only